UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 10-Q
|
ý |
QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 |
For the Quarterly Period Ended June 30, 2003
|
o |
TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 |
For the transition period from to
Commission file number: 0-25323
ALBANY MOLECULAR RESEARCH, INC.
(Exact name of registrant as specified in its charter)
|
DELAWARE |
|
14-1742717 |
|
(State or other jurisdiction of |
|
(I.R.S. Employer |
|
|
|
|
|
21 Corporate Circle |
||
|
PO Box 15098 |
||
|
Albany, New York 12212-5098 |
||
|
(Address of principal executive offices) |
||
|
|
|
|
|
(518) 464-0279 |
||
|
(Registrant’s telephone number, including area code) |
||
|
|
|
|
|
N/A |
||
|
(Former name, former address and former fiscal year, if changed since last report) |
||
Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days.
Yes ý No o
Indicate by check mark whether the registrant is an accelerated filer (as defined in Exchange Act Rule 12b-2).
Yes ý No o
Indicate the number of shares outstanding of each of the issuer’s classes of common stock, as of the latest practicable date.
Class |
|
Outstanding at July 31, 2003 |
Common Stock, $.01 par value |
|
31,801,931 |
ALBANY MOLECULAR RESEARCH, INC.
INDEX
|
|
|
|
|
|
|
3 |
||
|
|
|
|
|
|
|
|
3 |
|
|
|
|
4 |
|
|
|
|
5 |
|
|
|
|
Notes to Unaudited Condensed Consolidated Financial Statements |
6 |
|
|
|
|
|
|
|
Management’s Discussion and Analysis of Financial Condition and Results of Operations |
19 |
|
|
|
|
|
|
|
|
26 |
||
|
|
|
|
|
|
|
27 |
||
|
|
|
|
|
|
|
|||
|
|
|
|
|
|
|
27 |
||
|
|
|
|
|
|
|
27 |
||
|
|
|
|
|
|
|
29 |
||
2
PART I — FINANCIAL INFORMATION
Item 1. Condensed Consolidated Financial Statements
Albany Molecular Research, Inc.
Condensed Consolidated Statements of Income
(unaudited)
(Dollars in thousands, except for per share data)
|
|
|
Three Months Ended |
|
Six Months Ended |
|
||||||||
|
|
|
June 30, 2003 |
|
June 30, 2002 |
|
June 30, 2003 |
|
June 30, 2002 |
|
||||
|
|
|
|
|
|
|
|
|
|
|
||||
|
Contract revenue |
|
$ |
38,777 |
|
$ |
17,756 |
|
$ |
72,616 |
|
$ |
34,436 |
|
|
Recurring royalties |
|
15,200 |
|
14,075 |
|
26,300 |
|
24,800 |
|
||||
|
Total revenue |
|
53,977 |
|
31,831 |
|
98,916 |
|
59,236 |
|
||||
|
|
|
|
|
|
|
|
|
|
|
||||
|
Cost of contract revenue |
|
29,158 |
|
10,279 |
|
55,170 |
|
19,854 |
|
||||
|
Technology incentive award |
|
1,520 |
|
1,402 |
|
2,630 |
|
2,474 |
|
||||
|
Research and development |
|
5,552 |
|
2,097 |
|
11,117 |
|
3,716 |
|
||||
|
Selling, general and administrative |
|
5,304 |
|
3,254 |
|
11,433 |
|
6,311 |
|
||||
|
Total costs and expenses |
|
41,534 |
|
17,032 |
|
80,350 |
|
32,355 |
|
||||
|
|
|
|
|
|
|
|
|
|
|
||||
|
Income from operations |
|
12,443 |
|
14,799 |
|
18,566 |
|
26,881 |
|
||||
|
|
|
|
|
|
|
|
|
|
|
||||
|
Equity in (loss) income of unconsolidated affiliates |
|
(87 |
) |
779 |
|
(21 |
) |
1,269 |
|
||||
|
Interest income (expense), net |
|
354 |
|
988 |
|
560 |
|
2,104 |
|
||||
|
Other income, net |
|
110 |
|
6 |
|
122 |
|
85 |
|
||||
|
|
|
|
|
|
|
|
|
|
|
||||
|
Income before income tax expense |
|
12,820 |
|
16,572 |
|
19,227 |
|
30,339 |
|
||||
|
|
|
|
|
|
|
|
|
|
|
||||
|
Income tax expense |
|
4,551 |
|
6,013 |
|
6,826 |
|
11,012 |
|
||||
|
|
|
|
|
|
|
|
|
|
|
||||
|
Net income |
|
$ |
8,269 |
|
$ |
10,559 |
|
$ |
12,401 |
|
$ |
19,327 |
|
|
|
|
|
|
|
|
|
|
|
|
||||
|
Basic earnings per share |
|
$ |
0.26 |
|
$ |
0.32 |
|
$ |
0.39 |
|
$ |
0.59 |
|
|
|
|
|
|
|
|
|
|
|
|
||||
|
Diluted earnings per share |
|
$ |
0.26 |
|
$ |
0.32 |
|
$ |
0.38 |
|
$ |
0.58 |
|
See notes to unaudited condensed consolidated financial statements.
3
Albany Molecular Research, Inc.
Condensed Consolidated Balance Sheets
(Dollars in thousands)
|
|
|
June 30, |
|
December
31, |
|
||
|
|
|
(unaudited) |
|
|
|
||
|
Assets |
|
|
|
|
|
||
|
Current assets: |
|
|
|
|
|
||
|
Cash and cash equivalents |
|
$ |
47,802 |
|
$ |
34,838 |
|
|
Investment securities, available-for-sale |
|
74,829 |
|
94,699 |
|
||
|
Accounts receivable, net |
|
24,826 |
|
13,572 |
|
||
|
Royalty income receivable |
|
15,089 |
|
13,251 |
|
||
|
Inventory |
|
31,992 |
|
13,402 |
|
||
|
Unbilled services |
|
506 |
|
555 |
|
||
|
Prepaid expenses and other current assets |
|
5,270 |
|
2,776 |
|
||
|
Total current assets |
|
200,314 |
|
173,093 |
|
||
|
|
|
|
|
|
|
||
|
Property, plant and equipment, net |
|
137,579 |
|
||||